Gossamer's Phase 2 Trials Of Oral GB001 In Asthma And Chronic Rhinosinusitis Fail To Meet Main Goal

Shares of Gossamer Bio Inc. (GOSS) dropped more than 31 percent after the company said that two studies in GB001, phase 2b LEDA trial in moderate-to-severe eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, did not meet the primary endpoints. The company will discontinue development of GB001 in chronic rhinosinusitis.

In Tuesday pre-market trade, GOSS was trading at $9.30, down $4.29 or 31.57 percent.

The 480-subject LEDA study did not achieve statistical significance on the primary endpoint. But it was encouraged by the consistent results observed for all three doses of once-daily, oral GB001 therapy across the primary and secondary endpoints.

In addition, statistically significant improvements in the key secondary endpoint of time to first asthma worsening as compared to placebo were observed for GB001 20 mg and 60 mg, with GB001 40 mg also demonstrating a numeric improvement.

The company noted that the LEDA Study informed on the phase 3 registrational endpoint, the optimal patient population and dose selection for future studies.

Meanwhile, the company stated that the Phase 2 Titan study in 97 chronic rhinosinusitis patients has failed to meet primary endpoint as well as secondary endpoint. The safety and tolerability of GB001 40 mg was generally consistent with that observed in the LEDA Study. The company does not plan to continue further development of GB001 in chronic rhinosinusitis, Gossamer Bio said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google, owned by Alphabet Inc., plans to merge its teams working on Maps products and the mapping service Waze with effect from December 9, reports said. The decision to consolidate processes comes as the search giant is facing pressure to streamline operations and cut costs. The restructuring is expected to reduce overlapping work across the Waze and Maps products. The Pentagon announced that up to $9 billion worth of cloud-computing contracts were awarded to Google, Oracle, Amazon, and Microsoft. In a statement, the U.S. Department of Defense said, "The purpose of this contract is to provide the Department of Defense with enterprise-wide, globally available cloud services across all security domains and classification levels..." Juul Labs, an e-cigarette maker, said it has reached settlements with more than 5,000 vaping lawsuits in the United States. The cases were related to personal injury, consumer class action, government entity, and Native American tribes. In a statement, the company said it cannot disclose the settlement amount at this time as part of the settlement and court process.
Follow RTT